A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Subjects with Refractory Large B-CellLymphoma (ZUMA-14)
Safety and Efficacy of Axicabtagene Ciloleucel and Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma
Sponsor: Kite Pharma, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS2659
U.S. Govt. ID: NCT04002401
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if the experimental product, axicabtagene ciloleucel, in combination with either rituximab or lenalidomide is safe and effective in treating lymphoma. Kite Pharma, Inc., (Kite) is the sponsor of this study. The sponsor is funding this research study and has also designed the trial. The sponsor is testing an experimental treatment named axicabtagene ciloleucel in combination with either rituximab or lenalidomide. "Experimental" means that the drug combination in this study has not been approved for marketing by the United States Food and Drug Administration (FDA) in the USA or health regulatory authorities in other countries. All study participants will receive either axicabtagene ciloleucel and rituximab or axicabtagene ciloleucel and lenalidomide.
This study is closed
Ran Reshef, MD
Do You Qualify?
Have you been diagnosed with large B-cell lymphoma? Yes No
Are you 18 years of age or older? Yes No
Did your cancer not respond or get worse after chemotherapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator